Jeffrey R Tseng1, Keon Wook Kang2, Mangal Dandekar1, Shahriar Yaghoubi1, Joseph H Lee3, James G Christensen3, Stephen Muir4, Patrick W Vincent5, Neil R Michaud5, Sanjiv S Gambhir1,6. 1. Molecular Imaging Program at Stanford, Bio-X Program, and Department of Radiology, Stanford University, Stanford, California. 2. Department of Nuclear Medicine, National Cancer Center, Goyang, South Korea. 3. Cancer Biology, PGRD-La Jolla Laboratories, Pfizer Inc., La Jolla, California. 4. Oncology, PGRD-New London, Pfizer, Inc., New London, Connecticut. 5. Cancer Biology, PGRD-Groton Laboratories, Pfizer Inc., Groton, Connecticut. 6. Department of Bioengineering, Stanford University, Stanford, California.
Abstract
UNLABELLED: The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using (18)F-FDG small-animal PET. METHODS: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using (18)F-FDG small-animal PET and compared with tumor volume growth curves. RESULTS: The maximum %ID/g (percentage injected dose per gram of tissue) of (18)F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of (18)F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment. CONCLUSION: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of (18)F-FDG PET to assess early tumor response for CE-355621.
UNLABELLED: The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using (18)F-FDG small-animal PET. METHODS: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using (18)F-FDG small-animal PET and compared with tumor volume growth curves. RESULTS: The maximum %ID/g (percentage injected dose per gram of tissue) of (18)F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of (18)F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment. CONCLUSION: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of (18)F-FDG PET to assess early tumor response for CE-355621.
Authors: Nobuyuki Oyama; Joonyoung Kim; Lynne A Jones; Nicole M Mercer; John A Engelbach; Terry L Sharp; Michael J Welch Journal: Nucl Med Biol Date: 2002-11 Impact factor: 2.408
Authors: Barbara J Fueger; Johannes Czernin; Isabel Hildebrandt; Chris Tran; Benjamin S Halpern; David Stout; Michael E Phelps; Wolfgang A Weber Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Hossein Jadvar; Li Xiankui; Antranik Shahinian; Ryan Park; Michel Tohme; Jacek Pinski; Peter S Conti Journal: Mol Imaging Date: 2005 Apr-Jun Impact factor: 4.488
Authors: Elaine M Jagoda; Sibaprasad Bhattacharyya; Joseph Kalen; Lisa Riffle; Avrum Leeder; Stephanie Histed; Mark Williams; Karen J Wong; Biying Xu; Lawrence P Szajek; Osama Elbuluk; Fabiola Cecchi; Kristen Raffensperger; Meghana Golla; Donald P Bottaro; Peter Choyke Journal: Mol Imaging Date: 2015 Impact factor: 4.488
Authors: Carmel T Chan; Robert E Reeves; Ron Geller; Shahriar S Yaghoubi; Aileen Hoehne; David E Solow-Cordero; Gabriela Chiosis; Tarik F Massoud; Ramasamy Paulmurugan; Sanjiv S Gambhir Journal: Proc Natl Acad Sci U S A Date: 2012-08-15 Impact factor: 11.205
Authors: Anuradha Soundararajan; Jinu Abraham; Laura D Nelon; Suresh I Prajapati; Lee Ann Zarzabal; Joel E Michalek; Stanton F McHardy; Douglas S Hawkins; Suman Malempati; Charles Keller Journal: Pediatr Blood Cancer Date: 2012-01-11 Impact factor: 3.167
Authors: Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas Journal: Am J Nucl Med Mol Imaging Date: 2013-01-05
Authors: Jianhua Zhou; Huaijun Wang; Huiping Zhang; Amelie M Lutz; Lu Tian; Dimitre Hristov; Jürgen K Willmann Journal: Cancer Res Date: 2016-05-20 Impact factor: 12.701
Authors: Neil R Michaud; Jitesh P Jani; Stephen Hillerman; Konstantinos E Tsaparikos; Elsa G Barbacci-Tobin; Elisabeth Knauth; Henry Putz; Mary Campbell; George A Karam; Boris Chrunyk; David F Gebhard; Larry L Green; Jinghai J Xu; Margaret C Dunn; Tim M Coskran; Jean-Martin Lapointe; Bruce D Cohen; Kevin G Coleman; Vahe Bedian; Patrick Vincent; Shama Kajiji; Stefan J Steyn; Gary V Borzillo; Gerrit Los Journal: MAbs Date: 2012-09-24 Impact factor: 5.857